◎ Sugi Atlas

Atlas / Drug / Bemarituzumab

Bemarituzumab

drug
On this page

Also known as FPA-144

Summary

Bemarituzumab (CHEMBL4802165) is a phase-3 clinical-stage antibody targeting FGFR2 and FCGR3A; indicated across 5 conditions including adenocarcinoma and gastric neoplasm.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Antibody
  • Targets: 2 (FGFR2, FCGR3A)
  • Indications: 5 conditions
  • Clinical trials: 13

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL4802165
NameBemarituzumab
TypeAntibody
Max phase3

Also known as: Bemarituzumab, FPA-144, BEMARITUZUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
FGFR2fibroblast growth factor receptor 2Binding9.241.7%P21802
FCGR3AFc fragment of IgG receptor IIIaBinding8.040.1%P08637

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 2 target gene(s): FGFR2, FCGR3A.

Top Reactome pathways

24 total, by targets touching each:

PathwayTargetsGenes
PI3K Cascade1FGFR2
PIP3 activates AKT signaling1FGFR2
FGFR2c ligand binding and activation1FGFR2
FGFR2b ligand binding and activation1FGFR2
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell1FCGR3A
Signaling by FGFR2 amplification mutants1FGFR2
FCGR activation1FCGR3A
Regulation of actin dynamics for phagocytic cup formation1FCGR3A
Role of phospholipids in phagocytosis1FCGR3A
Activated point mutants of FGFR21FGFR2
Constitutive Signaling by Aberrant PI3K in Cancer1FGFR2
Phospholipase C-mediated cascade; FGFR21FGFR2
PI-3K cascade:FGFR21FGFR2
SHC-mediated cascade:FGFR21FGFR2
FRS-mediated FGFR2 signaling1FGFR2
Negative regulation of FGFR2 signaling1FGFR2
Signaling by FGFR2 in disease1FGFR2
RAF/MAP kinase cascade1FGFR2
FGFR2 alternative splicing1FGFR2
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling1FGFR2
Signaling by FGFR2 IIIa TM1FGFR2
Signaling by FGFR2 fusions1FGFR2
FCGR3A-mediated IL10 synthesis1FCGR3A
FCGR3A-mediated phagocytosis1FCGR3A

Dominant GO biological processes

GO termTargets
negative regulation of transcription by RNA polymerase II1
angiogenesis1
ureteric bud development1
in utero embryonic development1
epithelial to mesenchymal transition1
positive regulation of mesenchymal cell proliferation1
outflow tract septum morphogenesis1
membranous septum morphogenesis1
endochondral bone growth1
apoptotic process1
cell-cell signaling1
axonogenesis1
positive regulation of cell population proliferation1
fibroblast growth factor receptor signaling pathway1
regulation of smoothened signaling pathway1

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
adenocarcinoma2MONDO:0004970EFO:0000228
gastric neoplasm2MONDO:0021085MONDO:0001056
neoplasm1MONDO:0005070EFO:0000616
non-small cell lung carcinoma1MONDO:0005233EFO:0003060

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 13.

Phase distribution

PhaseTrials
PHASE25
PHASE1/PHASE23
PHASE13
PHASE32

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05111626PHASE3ACTIVE_NOT_RECRUITINGBemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
NCT05052801PHASE3COMPLETEDBemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT05322577PHASE1/PHASE2ACTIVE_NOT_RECRUITINGA Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.
NCT06680622PHASE2ACTIVE_NOT_RECRUITINGBemarituzumab in FGFR2b+ Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed at Least One Prior Line of Palliative Chemotherapy
NCT07470840PHASE2NOT_YET_RECRUITINGSBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma
NCT02213289PHASE2COMPLETEDPANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
NCT03694522PHASE2COMPLETEDA Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer
NCT05325866PHASE1/PHASE2COMPLETEDA Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT06967987PHASE2WITHDRAWNStudy Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b
NCT07146919PHASE1/PHASE2WITHDRAWNAssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer
NCT06978062PHASE1NOT_YET_RECRUITINGPeri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment
NCT03343301PHASE1COMPLETEDA Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer
NCT05267470PHASE1TERMINATEDA Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

53 molecules share ≥1 primary target. Top 53 by shared-target count:

MoleculeSourceStatusShared targets
PAZOPANIBChEMBL + PubChemPhase 4 (approved)FGFR2
AXITINIBChEMBLPhase 4 (approved)FGFR2
BRIGATINIBChEMBLPhase 4 (approved)FGFR2
CERITINIBChEMBLPhase 4 (approved)FGFR2
DASATINIBChEMBLPhase 4 (approved)FGFR2
ERDAFITINIBChEMBLPhase 4 (approved)FGFR2
ERLOTINIBChEMBLPhase 4 (approved)FGFR2
FEDRATINIBChEMBLPhase 4 (approved)FGFR2
FUTIBATINIBChEMBLPhase 4 (approved)FGFR2
IBRUTINIBChEMBLPhase 4 (approved)FGFR2
INFIGRATINIBChEMBLPhase 4 (approved)FGFR2
LENVATINIBChEMBLPhase 4 (approved)FGFR2
MIDOSTAURINChEMBLPhase 4 (approved)FGFR2
NINTEDANIBChEMBLPhase 4 (approved)FGFR2
NINTEDANIB ESYLATEChEMBLPhase 4 (approved)FGFR2
PEMIGATINIBChEMBLPhase 4 (approved)FGFR2
PONATINIBChEMBLPhase 4 (approved)FGFR2
SORAFENIBChEMBLPhase 4 (approved)FGFR2
SUNITINIBChEMBLPhase 4 (approved)FGFR2
VANDETANIBChEMBLPhase 4 (approved)FGFR2
BRIVANIBChEMBLPhase 3FGFR2
CEDIRANIBChEMBLPhase 3FGFR2
DOVITINIBChEMBLPhase 3FGFR2
LESTAURTINIBChEMBLPhase 3FGFR2
LINIFANIBChEMBLPhase 3FGFR2
SEMAXANIBChEMBLPhase 3FGFR2
AKN-028ChEMBLPhase 2FGFR2
AT-9283ChEMBLPhase 2FGFR2
BMS-754807ChEMBLPhase 2FGFR2
DERAZANTINIBChEMBLPhase 2FGFR2
DORAMAPIMODChEMBLPhase 2FGFR2
E-7090ChEMBLPhase 2FGFR2
FEXAGRATINIBChEMBLPhase 2FGFR2
FGFR INHIBITOR DEBIO 1347ChEMBLPhase 2FGFR2
FISOGATINIBChEMBLPhase 2FGFR2
FORETINIBChEMBLPhase 2FGFR2
LIRAFUGRATINIBChEMBLPhase 2FGFR2
LUCITANIBChEMBLPhase 2FGFR2
MK-2461ChEMBLPhase 2FGFR2
OSI-632ChEMBLPhase 2FGFR2
R-406ChEMBLPhase 2FGFR2
REBASTINIBChEMBLPhase 2FGFR2
RESIGRATINIBChEMBLPhase 2FGFR2
RX-518ChEMBLPhase 2FGFR2
SEGIGRATINIBChEMBLPhase 2FGFR2
SU-014813ChEMBLPhase 2FGFR2
TANDUTINIBChEMBLPhase 2FGFR2
TOZASERTIBChEMBLPhase 2FGFR2
AfatinibPubChemApprovedFGFR2
CrizotinibPubChemApprovedFGFR2
GefitinibPubChemApprovedFGFR2
IdelalisibPubChemApprovedFGFR2
SelumetinibPubChemApprovedFGFR2

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot